Glybera, the gene therapy which is the most expensive drug in the world, is to be withdrawn from the market because it has proven to be a commercial failure. Amsterdam-headquartered firm uniQure ...
The company secured approval in Europe for Glybera (alipogene tiparvovec) in 2012. The therapy was approved to treat the ultra-rare disease hereditary lipoprotein lipase deficiency (LPLD), and was ...
The only other gene therapies to have made it to market so far are uniQure’s Glybera’s (alipogene tiparvovec), and GSK’s Strimvelis, but both have only gained EU approval. Glybera is a case ...
Approved last week (November 2) by the European Commission, uniQure’s Glybera utilizes viral vectors to deliver DNA encoding a lipid-processing enzyme to patients lacking a functional copy due to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback